For Immediate Release
Promising New Therapeutic Strategy for Type 2 Diabetes Improves Cholesterol and Blood Sugar Control
Contact: Vicki Cohn
New Rochelle, NY, December 14, 2010—Bile acid sequestrants, a promising new class of drugs that could help more patients with diabetes achieve their goals for LDL cholesterol and blood glucose control, is the focus of a supplement to Metabolic Syndrome and Related Disorders, a peer-reviewed journal published by Mary Ann Liebert, Inc. The supplement is available free online.
Cardiovascular disease is the leading cause of death for people with diabetes, yet only about 12% of patients achieve adequate control of the main risk factors: glycated hemoglobin (HvA1c, a measure of long-term blood glucose control), LDL cholesterol, and blood pressure. A class of drugs called bile acid sequestrants, which include bile acid binding agents such as colesevelam and colestyramine, have demonstrated positive results in clinical studies in patients with type 2 diabetes.
The supplement focuses on the biological mechanism-of-action of these agents that contributes to their glucose- and cholesterol-lowering effects, their clinical utility, and their role in overall diabetes management. The articles describe the results of recent translational research and review the implications of these drugs in clinical practice.
In his Introduction, Ishwarlal (Kenny) Jialal, MD, PhD, Editor-in-Chief of the Journal and Robert E. Stowell Endowed Chair in Experimental Pathology, Director of the Laboratory for Atherosclerosis and Metabolic Research, and Professor of Internal Medicine at the University of California, Davis Medical Center (Sacramento), says that the supplement “provides a state-of-the-art update of the underappreciated use of BAS in diabetes treatment.”
Original articles are contributed by Janne Prawitt, PhD and Bart Staels, PhD, University of Lille Nord de France (“Bile Acid Sequestrants: Glucose-Lowering Mechanisms”); Philip Levy, MD, MACE, Phoenix, AZ (“Review of Studies on the Effect of Bile Acid Sequestrants in Patients with Type 2 Diabetes Mellitus”); and Om P. Ganda, MD, Harvard Medical School, in Boston, MA, (“The Role of Bile Acid Sequestrants in the Management of Type 2 Diabetes Mellitus”). In a summary and review of future directions, Yehuda Handelsman, MD, Metabolic Institute of America (Tarzana, CA), predicts that bile acid sequestrants will have a growing role in diabetes management, in both early and late disease, and presents an opportunity to control elevated blood glucose and cholesterol levels in patients with prediabetes.
Metabolic Syndrome and Related Disorders is the only peer-reviewed journal to focus solely on the pathophysiology, recognition, and treatment of metabolic syndrome. The Journal covers a range of topics including insulin resistance, central obesity, glucose intolerance, dyslipidemia with elevated triglycerides, predominance of small dense LDL-cholesterol particles, hypertension, endothelial dysfunction, and oxidative stress and inflammation. Table of contents and a free sample issues may be viewed online.